Voices
Eileen M O’Reilly: I have not seen this level of benefit from any single anti-cancer drug in this disease
Eileen M O’Reilly/Memorial Sloan Kettering Cancer Center 
Published by Semiramida M. MS, Editor-In-Chief OncoDaily Biotech
Fact checked by Sona K. MD, Medical Oncologist
Medically reviewed by Amalya S. MD, Medical Oncologist

Eileen M O’Reilly: I have not seen this level of benefit from any single anti-cancer drug in this disease

Memorial Sloan Kettering Cancer Center shared a post on X:

“The FDA has approved daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s Eileen M O’Reilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy.

‘To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease.’

Learn more about the approval and what it could mean for patients.”

Other articles about Memorial Sloan Kettering Cancer Center on OncoDaily.

Semiramida Markosyan

Author

Semiramida Markosyan

MS, Editor-In-Chief OncoDaily Biotech

Sona Karamyan
Fact checked by Sona Karamyan MD, Medical Oncologist
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist
DaraxONRASib Eileen M. O'Reilly FDA approval Memorial Sloan Kettering Cancer Center Revolution Medicine